Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of “Moderate Buy” from Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has earned an average rating of “Moderate Buy” from the thirteen analysts that are currently covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $48.67.

KYMR has been the subject of several analyst reports. Morgan Stanley upped their price objective on Kymera Therapeutics from $34.00 to $45.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 14th. Leerink Partnrs raised Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price objective on shares of Kymera Therapeutics in a research note on Monday, June 17th. Oppenheimer reaffirmed an “outperform” rating and set a $52.00 price objective on shares of Kymera Therapeutics in a research note on Wednesday, July 10th. Finally, B. Riley upped their price objective on Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, July 9th.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock opened at $49.03 on Friday. Kymera Therapeutics has a fifty-two week low of $9.60 and a fifty-two week high of $50.69. The company has a market capitalization of $3.01 billion, a P/E ratio of -19.53 and a beta of 2.22. The stock has a 50-day simple moving average of $44.93 and a 200-day simple moving average of $38.97.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.10. The firm had revenue of $25.60 million during the quarter, compared to the consensus estimate of $12.55 million. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The firm’s revenue was up 55.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.67) EPS. As a group, analysts forecast that Kymera Therapeutics will post -2.87 earnings per share for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 453,960 shares of the stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the sale, the director now owns 723,246 shares in the company, valued at approximately $27,635,229.66. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Kymera Therapeutics news, Director Bruce Booth sold 453,960 shares of the stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the transaction, the director now owns 723,246 shares of the company’s stock, valued at approximately $27,635,229.66. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $49.10, for a total value of $245,500.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 495,605 shares of company stock worth $19,303,364. 15.82% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in KYMR. Algert Global LLC raised its position in shares of Kymera Therapeutics by 16.5% in the 2nd quarter. Algert Global LLC now owns 32,706 shares of the company’s stock worth $976,000 after buying an additional 4,622 shares during the period. Driehaus Capital Management LLC purchased a new position in shares of Kymera Therapeutics in the 2nd quarter worth $6,669,000. Susquehanna Fundamental Investments LLC raised its position in shares of Kymera Therapeutics by 7.4% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 76,818 shares of the company’s stock worth $2,293,000 after buying an additional 5,325 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Kymera Therapeutics by 13.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 130,077 shares of the company’s stock worth $3,883,000 after buying an additional 15,320 shares during the period. Finally, Squarepoint Ops LLC raised its position in shares of Kymera Therapeutics by 27.3% in the 2nd quarter. Squarepoint Ops LLC now owns 108,563 shares of the company’s stock worth $3,241,000 after buying an additional 23,312 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.